March 16, 2022 6:44 pm
Pfizer-BioNTech filed an application with US regulators seeking emergency use authorization for a second booster shot of their Covid-19 vaccine for people aged 65 and older.
February 05, 2022 1:52 pm
In the United States, the recommended interval between the first two shots of Pfizer's vaccine is three weeks and for Moderna's, four.
February 01, 2022 1:54 pm
Coronavirus vaccines for children younger than 5 could be available as soon as end-February under a plan that would lead to the potential authorisation of a two-shot regimen in the coming weeks.
December 23, 2021 12:53 pm
Pfizer's Covid-19 antiviral drug Paxlovid has received emergency use authorisation in the United States. Several Indian drug manufacturers are already planning to manufacture the generic version on it.
November 09, 2021 3:03 pm
Pfizer and Merck have developed experimental antiviral pills that have shown promising efficacy in trials of adults with Covid-19 who are at high risk of serious illness. Here is an explanation of the differences in the two pills.
November 03, 2021 4:19 pm
To help immunocompromised people mount a more aggressive immune response, the CDC suggests that they be given three doses of Pfizer or Moderna vaccines, plus an additional booster shot six months after the third dose.
October 27, 2021 7:55 am
A Food and Drug Administration advisory panel voted unanimously, with one abstention, that the vaccine’s benefits in preventing COVID-19 in that age group outweigh any potential risks.
October 05, 2021 4:59 pm
The filing comes after the FDA last week scheduled an Oct. 15 meeting of its expert advisory committee to discuss whether to authorize a second shot of J&J's single-dose vaccine.
September 23, 2021 11:04 am
The booster dose is to be administered at least six months after completion of the second dose, and the authorization would include people most susceptible to severe disease and those in jobs that left them at risk, the FDA said.
September 07, 2021 10:11 am
Moderna vs Pfizer: The findings are significant because these results mark another step towards scientists determining whether one Covid-19 vaccine may be superior for certain demographics.